Recombinant lentivector as a genetic immunization vehicle for antitumor immunity

Yukai He, David Munn, Louis D. Falo

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Encouraged by remarkable successes in preventing infectious diseases and by the well-established potential of the immune system for controlling tumor growth, active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, engineered recombinant viral vectors have been carefully examined as genetic-immunization vehicles and have been demonstrated to induce potent T-cell-mediated immune responses that can control tumor growth. Very recent efforts suggest that lentivectors possess important advantages over other candidate recombinant viral vectors for genetic immunization. Here, we review the development of recombinant lentivectors and the characteristics of T-cell immune responses elicited by lentivector immunization, including the mechanism of T-cell priming with a focus on the role of skin dendritic cells and potential applications for tumor immunotherapy.

Original languageEnglish (US)
Pages (from-to)913-924
Number of pages12
JournalExpert Review of Vaccines
Issue number6
StatePublished - Dec 2007


  • Dendritic cell subsets
  • Gene delivery
  • Genetic immunization
  • Lentivector (lentiviral vector)
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Recombinant lentivector as a genetic immunization vehicle for antitumor immunity'. Together they form a unique fingerprint.

Cite this